全文获取类型
收费全文 | 1865篇 |
免费 | 130篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 75篇 |
妇产科学 | 80篇 |
基础医学 | 234篇 |
口腔科学 | 27篇 |
临床医学 | 140篇 |
内科学 | 459篇 |
皮肤病学 | 23篇 |
神经病学 | 267篇 |
特种医学 | 41篇 |
外科学 | 237篇 |
综合类 | 14篇 |
一般理论 | 2篇 |
预防医学 | 150篇 |
眼科学 | 48篇 |
药学 | 78篇 |
肿瘤学 | 107篇 |
出版年
2023年 | 19篇 |
2022年 | 41篇 |
2021年 | 78篇 |
2020年 | 37篇 |
2019年 | 72篇 |
2018年 | 70篇 |
2017年 | 41篇 |
2016年 | 65篇 |
2015年 | 73篇 |
2014年 | 76篇 |
2013年 | 92篇 |
2012年 | 119篇 |
2011年 | 112篇 |
2010年 | 72篇 |
2009年 | 78篇 |
2008年 | 108篇 |
2007年 | 111篇 |
2006年 | 108篇 |
2005年 | 82篇 |
2004年 | 87篇 |
2003年 | 66篇 |
2002年 | 62篇 |
2001年 | 17篇 |
2000年 | 17篇 |
1999年 | 11篇 |
1998年 | 10篇 |
1997年 | 6篇 |
1995年 | 8篇 |
1994年 | 6篇 |
1992年 | 12篇 |
1991年 | 11篇 |
1990年 | 18篇 |
1989年 | 19篇 |
1988年 | 9篇 |
1987年 | 10篇 |
1986年 | 11篇 |
1985年 | 13篇 |
1984年 | 14篇 |
1983年 | 14篇 |
1982年 | 10篇 |
1981年 | 16篇 |
1980年 | 9篇 |
1979年 | 8篇 |
1978年 | 10篇 |
1976年 | 8篇 |
1974年 | 10篇 |
1973年 | 7篇 |
1970年 | 6篇 |
1969年 | 8篇 |
1967年 | 6篇 |
排序方式: 共有2000条查询结果,搜索用时 15 毫秒
41.
Gregor K Wenning Felix Geser Florian Krismer Klaus Seppi Susanne Duerr Sylvia Boesch Martin Köllensperger Georg Goebel Karl P Pfeiffer Paolo Barone Maria Teresa Pellecchia Niall P Quinn Vasiliki Koukouni Clare J Fowler Anette Schrag Christopher J Mathias Nir Giladi Tanya Gurevich Werner Poewe 《Lancet neurology》2013,12(3):264-274
42.
Victoria C. Wing Mera S. Barr Caroline E. Wass Nir Lipsman Andres M. Lozano Zafiris J. Daskalakis Tony P. George 《Brain stimulation》2013,6(3):221-230
BackgroundTobacco smoking is the leading cause of preventable deaths worldwide, but many smokers are simply unable to quit. Psychosocial and pharmaceutical treatments have shown modest results on smoking cessation rates, but there is an urgent need to develop treatments with greater efficacy. Brain stimulation methods are gaining increasing interest as possible addiction therapeutics.ObjectivesThe purpose of this paper is to review the studies that have evaluated brain stimulation techniques on tobacco addiction, and discuss future directions for research in this novel area of addiction interventions.MethodsElectronic and manual literature searches identified fifteen studies that administered repetitive transcranial magnetic stimulation (rTMS), cranial electrostimulation (CES), transcranial direct current stimulation (tDCS) or deep brain stimulation (DBS).ResultsrTMS was found to be the most well studied method with respect to tobacco addiction. Results indicate that rTMS and tDCS targeted to the dorsolateral prefrontal cortex (DLPFC) were the most efficacious in reducing tobacco cravings, an effect that may be mediated through the brain reward system involved in tobacco addiction. While rTMS was shown to reduce consumption of cigarettes, as yet no brain stimulation technique has been shown to significantly increase abstinence rates. It is possible that the therapeutic effects of rTMS and tDCS may be improved by optimization of stimulation parameters and increasing the duration of treatment.ConclusionAlthough further studies are needed to confirm the ability of brain stimulation methods to treat tobacco addiction, this review indicates that rTMS and tDCS both represent potentially novel treatment modalities. 相似文献
43.
Amson M Lamoureux E Hilzenrat N Tischkowitz M 《Journal canadien de gastroenterologie》2012,26(6):330-332
The authors describe two siblings, each with a different, rare genetic condition that affects liver function. The index case, the 18-year-old asymptomatic brother of a young man recently diagnosed with Wilson disease, presented for Wilson disease screening and was also found to have abnormal liver function suggestive of cholestasis. However, ceruloplasmin level, 24 h urine copper concentration and liver synthetic function were normal. Further hepatic investigations and genetic mutation analysis were performed, ultimately leading to a diagnosis of Alagille syndrome. He was treated with ursodiol, which resulted in normalization of his liver function tests. Subsequently, he was found to be a carrier for a mutation in the Wilson disease gene, ATP7B. In the present report, the potential implications of being a heterozygote for Wilson disease in the context of Alagille syndrome are discussed. Also stressed is that care must be exercised by the clinician when diagnosing family members who may present with two different disorders closely mimicking one another. 相似文献
44.
Colombo PC Ganda A Lin J Onat D Harxhi A Iyasere JE Uriel N Cotter G 《Heart failure reviews》2012,17(2):177-190
Although inflammation is a physiologic response designed to protect us from infection, when unchecked and ongoing it may cause
substantial harm. Both chronic heart failure (CHF) and chronic kidney disease (CKD) are known to cause elaboration of several
pro-inflammatory mediators that can be detected at high concentrations in the tissues and blood stream. The biologic sources
driving this chronic inflammatory state in CHF and CKD are not fully established. Traditional sources of inflammation include
the heart and the kidneys which produce a wide range of pro-inflammatory cytokines in response to neurohormones and sympathetic
activation. However, growing evidence suggests that non-traditional biomechanical mechanisms such as venous and tissue congestion
due to volume overload are also important as they stimulate endotoxin absorption from the bowel and peripheral synthesis and
release of pro-inflammatory mediators. Both during the chronic phase and, more rapidly, during acute exacerbations of CHF
and CKD, inflammation and congestion appear to amplify each other resulting in a downward spiral of worsening cardiac, vascular,
and renal functions that may negatively impact patients’ outcome. Anti-inflammatory treatment strategies aimed at attenuating
end organ damage and improving clinical prognosis in the cardiorenal syndrome have been disappointing to date. A new therapeutic
paradigm may be needed, which involves different anti-inflammatory strategies for individual etiologies and stages of CHF
and CKD. It may also include specific (short-term) anti-inflammatory treatments that counteract inflammation during the unsettled
phases of clinical decompensation. Finally, it will require greater focus on volume overload as an increasingly significant
source of systemic inflammation in the cardiorenal syndrome. 相似文献
45.
Anat Mirelman PhD Talia Heman MsPT Kira Yasinovsky BS Avner Thaler MD Tanya Gurevich MD Karen Marder MD Susan Bressman MD Anat Bar‐Shira PhD Avi Orr‐Urtreger MD PhD Nir Giladi MD Jeffrey M. Hausdorff PhD 《Movement disorders》2013,28(12):1683-1690
Patients with Parkinson's disease (PD) who carry the G2019S mutation (a glycine to serine substitution at amino acid 2019) in the leucine‐rich repeat kinase 2 (LRRK2) gene are generally believed to be clinically indistinguishable from patients with sporadic PD. There are, however, conflicting reports on the relationship between the mutation and the motor phenotype. We quantitatively compared gait and mobility in patients with PD carriers of the G2019S mutation to non‐carrier patients with PD to better understand the genotype‐phenotype relationship. Fifty patients with PD carriers of the G2019S LRRK2 mutation and 50 age, disease duration, and disease severity matched PD non‐carriers were studied. An accelerometer quantified gait under three walking conditions: usual‐walking, dual‐tasking, and fast‐walking. The Unified Parkinson's Disease Rating Scale classified patients into PD sub‐types and the Timed Up and Go quantified mobility and fall risk. In all three walking conditions, gait variability was larger and the walking pattern was less consistent among the PD mutation carriers (P < 0.016). The PD carriers also took longer to complete the Timed Up and Go (P = 0.011) and were more likely to report having fallen in the previous year (P = 0.018). 64% of the PD carriers were classified as belonging to the postural‐instability‐gait‐difficulty (PIGD) sub‐type compared to only 17% of the PD non‐carriers (P < 0.0001). Among patients with PD, the G2019S mutation in the LRRK2 gene is apparently associated with increased gait variability, an increased fall risk, and the PIGD sub‐type. Therapeutic approach specifically designed to delay gait disturbances and falls may be justified in patients who carry the G2019S mutation. © 2013 International Parkinson and Movement Disorder Society 相似文献
46.
47.
Nurit Omer MD Nir Giladi MD Tanya Gurevich MD Anat Bar-Shira PhD Mali Gana-Weisz PhD Tal Glinka MSc Orly Goldstein PhD Meir Kestenbaum MD Jesse M. Cedarbaum MD Omar S. Mabrouk PhD Kyle B. Fraser PhD Julia C. Shirvan MD PhD Avi Orr-Urtreger MD PhD Anat Mirelman PhD Avner Thaler MD PhD 《Movement disorders》2022,37(1):190-195
48.
Koerte Inga K. Bahr Roald Filipcik Peter Gooijers Jolien Leemans Alexander Lin Alexander P. Tripodis Yorghos Shenton Martha E. Sochen Nir Swinnen Stephan P. Pasternak Ofer 《Brain imaging and behavior》2022,16(1):492-502
Brain Imaging and Behavior - Repetitive head impacts (RHI) are common in youth athletes participating in contact sports. RHI differ from concussions; they are considered hits to the head that... 相似文献
49.
Marcus R. Pereira Sumit Mohan David J. Cohen Syed A. Husain Geoffrey K. Dube Lloyd E. Ratner Selim Arcasoy Meghan M. Aversa Luke J. Benvenuto Darshana M. Dadhania Sandip Kapur Lorna M. Dove Robert S. Brown Russell E. Rosenblatt Benjamin Samstein Nir Uriel Maryjane A. Farr Michael Satlin Catherine B. Small Thomas J. Walsh Rosy P. Kodiyanplakkal Benjamin A. Miko Justin G. Aaron Demetra S. Tsapepas Jean C. Emond Elizabeth C. Verna 《American journal of transplantation》2020,20(7):1800-1808
Solid organ transplant recipients may be at a high risk for SARS‐CoV‐2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS‐CoV‐2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). Ninety patients were analyzed with a median age of 57 years. Forty‐six were kidney recipients, 17 lung, 13 liver, 9 heart, and 5 dual‐organ transplants. The most common presenting symptoms were fever (70%), cough (59%), and dyspnea (43%). Twenty‐two (24%) had mild, 41 (46%) moderate, and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non‐rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID‐19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID‐19 has the potential to severely impact solid organ transplant recipients. 相似文献
50.